Outcomes of infliximab dose escalation in patients with rheumatoid arthritis

被引：0
|
作者：
Stanley B. Cohen
Joel M. Kremer
Kimberly J. Dandreo
George W. Reed
Robert Magner
Ying Shan
Shelly Kafka
Raphael J. DeHoratius
Lorie Ellis
Dennis Parenti
机构：
[1] Metroplex Clinical Research Center,The Center for Rheumatology
[2] Albany Medical College,Sidney Kimmel School of Medicine
[3] Corrona,undefined
[4] LLC,undefined
[5] University of Massachusetts Medical School,undefined
[6] Janssen Scientific Affairs,undefined
[7] LLC,undefined
[8] Thomas Jefferson University,undefined
来源：
Clinical Rheumatology | 2019年 / 38卷
关键词：
Dose escalation; Infliximab; Patient registry; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2501 / 2508
页数：7
相关论文
共 50 条
  • [1] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Cohen, Stanley B.
    Kremer, Joel M.
    Dandreo, Kimberly J.
    Reed, George W.
    Magner, Robert
    Shan, Ying
    Kafka, Shelly
    DeHoratius, Raphael J.
    Ellis, Lorie
    Parenti, Dennis
    [J]. CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2501 - 2508
  • [2] Dose escalation of infliximab in rheumatoid arthritis
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (04) : A6 - A6
  • [3] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
  • [4] Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment
    Van Looy, Stijn
    Cruyssen, Bert Vander
    Meeus, Jeroen
    Wyns, Bart
    Westhovens, Rene
    Durez, Patrick
    Van den Bosch, Filip
    Vastesaeger, Nathan
    Geldhof, Anja
    Boullart, Luc
    De Keyser, Filip
    [J]. ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE, 2006, 19 (07) : 819 - 828
  • [5] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Wagner, C.
    Han, J.
    Westhovens, R.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 86 - 86
  • [6] Infliximab dose escalation in patients with rheumatoid arthritis in the start trial: The effect of infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Berman, A.
    Wagner, C.
    Fasanmade, A.
    Han, J.
    Westhovens, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 184 - 185
  • [7] Infliximab dose escalation in patients with rheumatoid arthritis: Results from the start trial
    Westhovens, R
    Wolfe, F
    Rahman, MU
    Han, J
    Yocum, D
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 423 - 423
  • [8] CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis
    Tesser, John
    Black, Shawn
    Lin, Rongshuang
    Langholff, Wayne
    Uy, Jonathan
    Kafka, Shelly
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [9] Infliximab dose escalation in patients with rheumatoid arthritis: Results from the START trial.
    Westhovens, R
    Wolfe, F
    Rahman, MU
    Han, J
    Yocum, D
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S185 - S186
  • [10] COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
    Garces, K.
    Thorne, C.
    Boire, G.
    Chow, A.
    Poulin-Costello, M.
    Walker, V
    Haraoui, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A229 - A230
12345